Latigo Biotherapeutics Inc LTGO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Latigo Biotherapeutics Announces CEO Transition to Support the Company’s Next Phase of Growth
Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Trading Information
- Previous Close Price
- $13.01
- Day Range
- $12.39–14.66
- 52-Week Range
- $10.70–25.70
- Bid/Ask
- $12.10 / $12.67
- Shares Outstanding
- 66.30M
- Market Cap
- $1.06B
- Volume/Avg
- 623 / 334,726
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.latigobio.com
Valuation
Metric | LTGO |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | LTGO |
|---|---|
Quick Ratio | 1.07 |
Current Ratio | 1.15 |
Interest Coverage | — |
Quick Ratio
LTGO
Profitability
Metric | LTGO |
|---|---|
Return on Assets (Normalized) | −161.35% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
LTGO
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|C<??fH! | LOCK|NV!JS | $138B | |||
| Moderna Inc MRNA | LOCK|f>^@<>> | LOCK|bMN | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|vgTPm? | LOCK|Qr<kW | $93B | |||
| argenx SE ADR ARGX | LOCK|@K!g$^ | LOCK|Lmk | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|<@?P^Zz | LOCK|%l | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|h>bB@bb | LOCK|&gl^% | $30B | |||
| Incyte Corp INCY | LOCK|W$>jBF< | LOCK|B@ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|SP$<!j | LOCK|S< | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|ShDfcB | LOCK|h?g< | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|$#w$l^ | LOCK|#<r | $15B |
United States